Drug Profile
Acetalin 2 - RELIEF THERAPEUTICS Holding
Alternative Names: Ac-RFMWMR-NH2 - RELIEF THERAPEUTICSLatest Information Update: 18 Sep 2023
Price :
$50
*
At a glance
- Originator mondoBIOTECH
- Developer RELIEF THERAPEUTICS Holding
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Hepatitis B; Tuberculosis
Most Recent Events
- 18 Sep 2023 Discontinued - Preclinical for Hepatitis B in Switzerland (unspecified route) (RELIEF THERAPEUTICS pipeline, September 2023)
- 18 Sep 2023 Discontinued - Preclinical for Tuberculosis in Switzerland (unspecified route) (RELIEF THERAPEUTICS pipeline, September 2023)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Hepatitis-B in Switzerland